The addition of the Frankfurt-based contract research organization has boosted Kymos’s activities in the biologics and advanced therapies market, also broadening its service offering to biopharmaceutical companies worldwide.

Kymos said the companies’ combined expertise will allow them to offer a unique selection of services for innovative small and large molecules, generics, biosimilars, antibodies, biomarkers, anti-drug antibodies, antibody-drug conjugates, hormones, enzymes and nucleic acids.

Interest in recombinant proteins and in advanced cell and gene therapies is booming, both in Europe and worldwide, said Kymos, pointing out that Prolytic also has experience in mRNA technologies, which are being used in Covid-19 vaccines currently under development in Europe.

“The knowledge that Prolytic has regarding DNA and RNA is a key scientific element of the advanced therapies services market that Kymos is entering,” said Joan Puig de Dou, CEO at Kymos. “The merger gives us the opportunity to increase our service offering, strengthen the emerging therapies market and create a multinational and multidisciplinary company.

Following the merger, Kymos now has three sites in Europe – Barcelona, Spain; Ancona, Italy; and Frankfurt, Germany.

Having strengthened its already prominent presence in Europe, Kymos said it now aims to expand into the Asia-Pacific region, while opening up promising new therapeutic areas.

Author: Elaine Burridge, Freelance Journalist